Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04064411 · ClinicalTrials.gov registry record · Phase 3
Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
A Phase 3 study of Postmenopausal Osteoporosis, sponsored by Radius Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 511
- Enrollment target
- 20
- Study locations
NCT04064411 is a Phase 3 study of Postmenopausal Osteoporosis that has completed, run by Radius Health. The registered enrollment target is 511 participants, roughly in line with the 544-participant average among 12 other Postmenopausal Osteoporosis trials with a reported enrollment target. The trial reports 20 study locations across 8 states.
The verdict
NCT04064411, a Phase 3 study of Postmenopausal Osteoporosis, has completed, sponsored by Radius Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 511 participants
- Enrollment target
- 20
- Study locations
Study Summary
A 12-month study to compare the efficacy and safety of abaloparatide-solid microstructured transdermal system (sMTS) with abaloparatide-subcutaneous (SC).
Conditions Studied
Interventions
- COMBINATION_PRODUCT abaloparatide
- COMBINATION_PRODUCT abaloparatide solid microstructured transdermal system
Study Locations (20)
California
- Advanced Clinical Research (ACR) - Rancho Paseo - Banning
- Osteoporosis Medical Center - Beverly Hills
- Clinical Trials of St. Jude Heritage Medical Group through S - Fullerton
- Allied Clinical Research - Gold River
- Marin Endocrine Care & Research, Inc. - Greenbrae
- St. Joseph Heritage Healthcare - Mission Viejo
- Northern California Institute for Bone Health Inc. - Orinda
- Alta California Medical Group, Inc. - Simi Valley
Arizona
- Arizona Arthritis & Rheumatology Research, PLLC - Research Center - Glendale - Glendale
- Arizona Arthritis & Rheumatology Research, PLLC - Mesa
- SunValley Arthritis Center Ltd. - Peoria
- Clinical Research Consortium - Tempe
Florida
- UNC School of Medicine - Boca Raton
- Bay Area Arthritis And Osteoporosis - Brandon
- Clinical Research of West Florida - Clearwater
Alabama
- University of Alabama Hospital at Birmingham - Birmingham
Alaska
- Orthopedic Physician Alaska - Rheumatology - Anchorage
Arkansas
- Arthritis & Rheumatism - Jonesboro
Colorado
- Lynn Institute of Denver - Aurora
District of Columbia
- MedStar Georgetown University Hospital - Department of Obstetrics and Gynecology - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 511 participants |
| Start Date | 2019-08-05 |
| Est. Completion | 2021-11-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04064411
The ClinicalTrials.gov registry entry for NCT04064411 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 511 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 544-participant average among 12 other Postmenopausal Osteoporosis trials with a reported enrollment target. The listed sponsor is Radius Health, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Postmenopausal Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which abaloparatide is the first listed.
NCT04064411 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT04064411 about?
NCT04064411 is a clinical study titled "Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis". A 12-month study to compare the efficacy and safety of abaloparatide-solid microstructured transdermal system (sMTS) with abaloparatide-subcutaneous (SC).
What is the current status of trial NCT04064411?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 511 participants. The study started on 2019-08-05. Estimated completion is 2021-11-09.
What conditions does trial NCT04064411 study?
This clinical trial studies the following conditions: Postmenopausal Osteoporosis.
What interventions are being tested in trial NCT04064411?
The interventions under investigation include: abaloparatide (COMBINATION_PRODUCT), abaloparatide solid microstructured transdermal system (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04064411?
This trial is sponsored by Radius Health, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04064411 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postmenopausal Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Monthly Risedronate for Osteoporosis
COMPLETED · Phase 3
-
A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
COMPLETED · Phase 3
-
Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis
COMPLETED · Phase 3
-
An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
COMPLETED · Phase 3
-
Dried Plums and Bone Health in Postmenopausal Women
ACTIVE NOT RECRUITING · NA
-
A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.